Biology subjects

Davies, E. J.

Publications and source records attributed to Davies, E. J..

4 recordsLinked to original sources

bioRxiv2026

Longitudinal fMRI reveals altered developmental trajectories of functional network organisation associated with adolescent cannabis use

Adolescence is a critical period of brain development during which the endocannabinoid system continues to mature. These developmental changes may contribute to age-related differences in the association between cannabis use and large-scale functional network organisation, yet this association remains incompletely characterised. We hypothesised that regular cannabis use would be associated with differential one-year changes in resting-state functional connectivity between adolescents and adults. Resting-state fMRI data at two time points, one year apart, were analysed from 66 participants (31 aged 16-17 years; 35 aged 26-29 years) including 29 with regular cannabis use and 37 age-matched cannabis-naive controls. Seed-to-voxel analyses examined longitudinal changes in functional connectivity across age and cannabis-use groups. Year change, age by user-group interactions were identified in salience and default mode network connectivity, including divergent changes in anticorrelations with medial prefrontal, thalamic, cerebellar and juxtapositional regions. Directionality of effects differed by network and region. Additional main effects of user group were observed for executive control and associative striatal connectivity, with the cannabis-use group showing decreased positive connectivity and reduced anticorrelation, respectively. Changes in functional connectivity were developmentally dissociable and predominantly observed in regions contributing to attentional and transmodal processing. These findings suggest that cannabis may be associated with alterations in the maturational refinement of higher-order neural systems, potentially reflecting age-related differences in neurobiological sensitivity to cannabis exposure. Considering developmental stage may therefore be important for characterising cannabis-related neurobiological differences and may have implications for understanding age-dependent vulnerability to cannabis-related psychiatric outcomes.

neuroscience↗

bioRxiv2025

Repurposing statins and phenothiazines to treat chemoresistant neuroblastoma.

Relapse and treatment resistance are common in children with high-risk neuroblastoma, and novel therapies are needed. Conventional drug discovery is slow, expensive, often fails in practice, and consequently falls short in addressing pediatric and rare conditions. In such instances, drug repurposing is a promising strategy. Here, we used two independent in silico prediction tools including machine learning to identify approved drugs for repurposing against neuroblastoma. The combination of statins and phenothiazines showed strong synergistic effects in human neuroblastoma organoids, decreased tumor growth and prolonged survival in MYCN-amplified neuroblastoma patient-derived xenografts. The drug combination altered cholesterol metabolism through a dual-hit mechanism and induced a phenotypic switch towards an adrenergic cell state accompanied by increased sensitivity to chemotherapy. Integration of the drug combination into standard-of-care chemotherapy regressed tumors and prolonged survival in chemoresistant patient-derived xenografts. Thus, a combination of safe and approved medications added to standard-of-care chemotherapy outperforms chemotherapy alone in chemoresistant neuroblastoma. TeaserUsing in silico prediction tools we repurposed statins and phenothiazines as a combination with translational potential in high-risk neuroblastoma.

cancer biology↗

bioRxiv2020

ObLiGaRe doxycycline Inducible (ODIn) Cas9 system driving pre-clinical drug discovery, from design to cancer treatment

The CRISPR-Cas9 system has increased the speed and precision of genetic editing in cells and animals. However, model generation for drug development is still expensive and time-consuming, demanding more target flexibility and faster turnaround times with high reproducibility. We have generated a tightly controlled ObLiGaRe doxycycline inducible SpCas9 (ODInCas9) transgene. Targeted ObLiGaRe resulted in functional integration into both human and mouse cells culminating in the generation of the ODInCas9 mouse. Genomic editing can be performed in cells of various tissue origins without any detectable gene editing in the absence of doxycycline. Somatic in vivo editing can model non-small cell lung cancer (NSCLC) adenocarcinomas, enabling treatment studies to validate the efficacy of candidate drugs. The ODInCas9 mouse can be utilized for robust and tunable genome editing allowing for flexibility, speed and uniformity at reduced cost, leading to high throughput and practical preclinical in vivo therapeutic testing.

genomics↗

bioRxiv2019

Generation and characterisation of an estrogen receptor-positive GEMM-derived Pten p53 null transplantable breast tumour model for therapeutic testing

Assessing the signalling pathway dependencies of tumours that arise autochthonously in genetically engineered mouse models (GEMMs) of breast cancer is particularly challenging due to the high degree of intra- and inter-tumour heterogeneity, as well as the long latency of tumour development in such models. Use of transplantable tumour lines derived from autochthonous tumours ( Mouse Derived Xenografts or MDXs) is one possible solution and has been used successfully in models of BRCA1-associated triple negative breast cancer. However, their potential in ER+ breast cancer models has not been addressed. Here, we assess the utility of orthotopic transplantable tumour lines derived from an autochthonous ER+ Blg-cre Ptenfl/fl p53fl/fl breast cancer model. We show that initial tumour implantation and early passage results in the development of lines of progeny with heterogeneous histopathological phenotypes which is coincident with an accumulation of, or selection for, de novo mutations. Importantly, these lines also display different dependencies on the key pathways that drive tumourigenesis, which can lead to inherent resistance to treatment with pharmacological agents targeting these pathways and makes them important models to test strategies to overcome such resistance.

cancer biology↗